{"id":9489,"date":"2020-11-30T10:49:51","date_gmt":"2020-11-30T18:49:51","guid":{"rendered":"https:\/\/todaysveterinarybusiness.com\/?p=9489"},"modified":"2022-06-15T17:46:40","modified_gmt":"2022-06-15T17:46:40","slug":"stelfonta-virbac-qbiotics","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/","title":{"rendered":"Virbac teams with QBiotics on cancer product"},"content":{"rendered":"

Virbac Corp. is getting into the veterinary oncology business through a partnership with QBiotics, the developer of an FDA-approved treatment for canine mast cell tumors.<\/p>\n

The prescription product, Stelfonta (tigilanol tiglate), is an intratumoral injection indicated for use on non-metastatic cutaneous mast cell tumors anywhere on the body or subcutaneous mast cell tumors<\/a> located at or distal to the canine elbow.<\/p>\n

\u201cAlthough surgery remains the standard of care for the majority of tumors, I believe Stelfonta will change our approach to controlling localized mast cell tumors in many ways,\u201d said Chad M. Johannes, DVM, DACVIM (SAIM, Oncology), an Iowa State University veterinary oncologist, who spoke on behalf of Virbac.<\/p>\n

\u201cStelfonta is administered by injection directly into the tumor,\u201d Dr. Johannes said. \u201cGenerally, dogs undergoing treatment do not require sedation or anesthesia, which carries a potential increased risk for older dogs and brachycephalic breeds.\u201d<\/p>\n

According to Virbac, 88% of dogs injected with Stelfonta achieved resolution of the target tumor within 28 days after the first or second treatment.<\/p>\n

Australia-based QBiotics developed Stelfonta using a chemical compound called phorbol ester, which is extracted from the seeds of the blushwood tree, a rainforest shrub. Terms of the partnership with Virbac were not revealed.<\/p>\n

The U.S. Food and Drug Administration approved Stelfonta in mid-November. European regulators authorized the product in early 2020.<\/p>\n

\u201cThis is the first approval for an intratumoral injection to treat non-metastatic mast cell tumors in dogs,\u201d said Steven M. Solomon, DVM, MPH, director of the FDA\u2019s Center for Veterinary Medicine. \u201cThis approval provides an additional treatment option to help treat local mast cell tumors on or under the skin in dogs.\u201d<\/p>\n

Virbac<\/a>, the maker of antibiotics, heartworm drugs and other small animal medications, is based in Westlake, Texas.<\/p>\n

\n

Did you know a subscription to Today\u2019s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here<\/a> (and renew each year). You also can sign up to receive the Today\u2019s Veterinary Business weekly e-newsletter.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

FDA-approved Stelfonta is an injectable treatment for certain mast cell tumors in dogs.<\/p>\n","protected":false},"author":45,"featured_media":9490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-9489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","column-news","clinical_topics-veterinary-products"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"\nVirbac teams with QBiotics on cancer product | Today's Veterinary Business<\/title>\n<meta name=\"description\" content=\"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virbac teams with QBiotics on cancer product\" \/>\n<meta property=\"og:description\" content=\"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/\" \/>\n<meta property=\"og:site_name\" content=\"Today's Veterinary Business\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/todaysveterinarybusiness\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T18:49:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-15T17:46:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"544\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Louise S. Dunn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:site\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Louise S. Dunn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/\"},\"author\":{\"name\":\"Louise S. Dunn\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\"},\"headline\":\"Virbac teams with QBiotics on cancer product\",\"datePublished\":\"2020-11-30T18:49:51+00:00\",\"dateModified\":\"2022-06-15T17:46:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/11\\\/Canine-Patient.jpg\",\"articleSection\":[\"Online\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/\",\"name\":\"Virbac teams with QBiotics on cancer product | Today's Veterinary Business\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/11\\\/Canine-Patient.jpg\",\"datePublished\":\"2020-11-30T18:49:51+00:00\",\"dateModified\":\"2022-06-15T17:46:40+00:00\",\"description\":\"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/11\\\/Canine-Patient.jpg\",\"contentUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/11\\\/Canine-Patient.jpg\",\"width\":1024,\"height\":544,\"caption\":\"Stelfonta\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/stelfonta-virbac-qbiotics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Virbac teams with QBiotics on cancer product\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"name\":\"Today's Veterinary Business\",\"description\":\"Veterinary Business Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\",\"name\":\"Today's Veterinary Business\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"contentUrl\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"width\":258,\"height\":71,\"caption\":\"Today's Veterinary Business\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/todaysveterinarybusiness\",\"https:\\\/\\\/x.com\\\/tvbpublication\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/todaysveterinarybusiness\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\",\"name\":\"Louise S. Dunn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"caption\":\"Louise S. Dunn\"},\"sameAs\":[\"http:\\\/\\\/www.tvb.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Virbac teams with QBiotics on cancer product | Today's Veterinary Business","description":"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Virbac teams with QBiotics on cancer product","og_description":"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.","og_url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/","og_site_name":"Today's Veterinary Business","article_publisher":"https:\/\/www.facebook.com\/todaysveterinarybusiness","article_published_time":"2020-11-30T18:49:51+00:00","article_modified_time":"2022-06-15T17:46:40+00:00","og_image":[{"width":1024,"height":544,"url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg","type":"image\/jpeg"}],"author":"Louise S. Dunn","twitter_card":"summary_large_image","twitter_creator":"@tvbpublication","twitter_site":"@tvbpublication","twitter_misc":{"Written by":"Louise S. Dunn","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#article","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/"},"author":{"name":"Louise S. Dunn","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb"},"headline":"Virbac teams with QBiotics on cancer product","datePublished":"2020-11-30T18:49:51+00:00","dateModified":"2022-06-15T17:46:40+00:00","mainEntityOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg","articleSection":["Online"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/","name":"Virbac teams with QBiotics on cancer product | Today's Veterinary Business","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#primaryimage"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg","datePublished":"2020-11-30T18:49:51+00:00","dateModified":"2022-06-15T17:46:40+00:00","description":"Virbac is entering the veterinary oncology business with the approval of Stelfonta, an injectable treatment for canine mast cell tumors.","breadcrumb":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#primaryimage","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg","contentUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/11\/Canine-Patient.jpg","width":1024,"height":544,"caption":"Stelfonta"},{"@type":"BreadcrumbList","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/stelfonta-virbac-qbiotics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/"},{"@type":"ListItem","position":2,"name":"Virbac teams with QBiotics on cancer product"}]},{"@type":"WebSite","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","name":"Today's Veterinary Business","description":"Veterinary Business Magazine","publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization","name":"Today's Veterinary Business","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/","url":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","contentUrl":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","width":258,"height":71,"caption":"Today's Veterinary Business"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/todaysveterinarybusiness","https:\/\/x.com\/tvbpublication","https:\/\/www.linkedin.com\/company\/todaysveterinarybusiness"]},{"@type":"Person","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb","name":"Louise S. Dunn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","caption":"Louise S. Dunn"},"sameAs":["http:\/\/www.tvb.com"]}]}},"_links":{"self":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/comments?post=9489"}],"version-history":[{"count":2,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9489\/revisions"}],"predecessor-version":[{"id":18574,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9489\/revisions\/18574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media\/9490"}],"wp:attachment":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media?parent=9489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/categories?post=9489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/tags?post=9489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}